Literature DB >> 21273642

Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice.

Abaineh Dagne1, Tamene Melkamu, Melissa M Schutten, Xuemin Qian, Pramod Upadhyaya, Xianghua Luo, Fekadu Kassie.   

Abstract

In earlier studies, we demonstrated the efficacy of indole-3-carbinol (I3C) against lung adenocarcinoma in A/J mice. However, these effects were accompanied by reductions in body weight gain. We therefore assessed if combinations of low doses of I3C with silibinin could inhibit lung tumorigenesis without causing undesirable side effects. In in vitro assays with A549 and H460 lung cancer cells, exposure of the cells to a mixture of low concentrations of I3C (50 μM) plus silibinin (50 μM) for 72 h caused inhibition of cell growth and extracellular signal-regulated kinase (ERK) and Akt activation and induction of apoptosis, whereas the individual agents did not have any effect. In mice pretreated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and given I3C (10 μmol/g diet) plus silibinin (7 μmol/g diet), multiplicities of tumors on the surface of the lung and adenocarcinoma were reduced by 60 and 95%, respectively. The individual effects of I3C and silibinin were relatively weaker: 43 and 36% reductions, respectively, in the multiplicity of tumors on the surface of the lung and 83 and 50% reductions, respectively, in the number of adenocarcinoma. Also, the expression of phospho-Akt, phospho-ERK and cyclin D1 and poly (ADP-ribose) polymerase cleavage were strongly modulated by I3C plus silibinin than by I3C or silibinin alone, suggesting that the chemopreventive activities of the mixture could be mediated, at least partly, via modulation of the level of these proteins. Taken together, our findings showed that mixtures of I3C and silibinin are more potent than the individual compounds for the chemoprevention of lung cancer in A/J mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273642      PMCID: PMC3066421          DOI: 10.1093/carcin/bgr010

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  32 in total

1.  Effect of silibinin on the growth and progression of primary lung tumors in mice.

Authors:  Rana P Singh; Gagan Deep; Manesh Chittezhath; Manjinder Kaur; Lori D Dwyer-Nield; Alvin M Malkinson; Rajesh Agarwal
Journal:  J Natl Cancer Inst       Date:  2006-06-21       Impact factor: 13.506

2.  Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model.

Authors:  K M Wahidur Rahman; Fazlul H Sarkar; Sanjeev Banerjee; Zhiwei Wang; Dezhong J Liao; Xin Hong; Nurul H Sarkar
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

Review 3.  Multitargeted therapy of cancer by silymarin.

Authors:  Kumaraguruparan Ramasamy; Rajesh Agarwal
Journal:  Cancer Lett       Date:  2008-05-09       Impact factor: 8.679

4.  Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogen-induced lung adenocarcinoma in mice.

Authors:  Fekadu Kassie; Ilze Matise; Mesfin Negia; David Lahti; Yunqian Pan; Robyn Scherber; Pramod Upadhyaya; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2008-09

5.  Dose-dependent inhibition of tobacco smoke carcinogen-induced lung tumorigenesis in A/J mice by indole-3-carbinol.

Authors:  Fekadu Kassie; Ilze Matise; Mesfin Negia; Pramod Upadhyaya; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2008-12

6.  Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Authors:  Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner
Journal:  Cancer Prev Res (Phila)       Date:  2008-06

7.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.

Authors:  Yoshitaka Nakamura; Shingo Yogosawa; Yasuyuki Izutani; Hirotsuna Watanabe; Eigo Otsuji; Tosiyuki Sakai
Journal:  Mol Cancer       Date:  2009-11-12       Impact factor: 27.401

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  15 in total

1.  [Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt].

Authors:  Yun Wang; Yuyuan Zhang; Xue Chen; Yun Hong; Zhengdong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Dietary agents for prevention and treatment of lung cancer.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2015-01-30       Impact factor: 8.679

Review 3.  Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Dejuan Kong; Bin Bao; Rainer Schobert; Subhash B Padhye; Fazlul H Sarkar
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

4.  Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.

Authors:  Mee-Hyun Lee; Zunnan Huang; Dong Joon Kim; Sung-Hyun Kim; Myoung Ok Kim; Sung-Young Lee; Hua Xie; Si Jun Park; Jae Young Kim; Joydeb Kumar Kundu; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-27

5.  Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities.

Authors:  Altaf Mohammed; Jennifer T Fox; Mark Steven Miller
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

6.  Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.

Authors:  Jung Min Song; Xuemin Qian; Kalkidan Molla; Fistum Teferi; Pramod Upadhyaya; Gerry O Sullivan; Xianghua Luo; Fekadu Kassie
Journal:  Carcinogenesis       Date:  2015-04-20       Impact factor: 4.944

7.  Indole-3-carbinol inhibited tobacco smoke carcinogen-induced lung adenocarcinoma in A/J mice when administered during the post-initiation or progression phase of lung tumorigenesis.

Authors:  Xuemin Qian; Tamene Melkamu; Pramod Upadhyaya; Fekadu Kassie
Journal:  Cancer Lett       Date:  2011-07-02       Impact factor: 8.679

8.  Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer.

Authors:  T Melkamu; X Qian; P Upadhyaya; M G O'Sullivan; F Kassie
Journal:  Vet Pathol       Date:  2013-02-04       Impact factor: 2.221

Review 9.  Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.

Authors:  Samiha Mateen; Komal Raina; Rajesh Agarwal
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

10.  Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

Authors:  Bhaskar Kahali; Stefanie B Marquez; Kenneth W Thompson; Jinlong Yu; Sarah J B Gramling; Li Lu; Aaron Aponick; David Reisman
Journal:  Carcinogenesis       Date:  2014-05-29       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.